Oncogenic BRAF noncanonically promotes tumor metastasis by mediating VASP phosphorylation and filopodia formation
- 9 September 2023
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 42 (43) , 3194-3205
Abstract
BRAF is frequently mutated in various cancer types and contributes to tumorigenesis and metastasis. As an important switch in RAS signaling pathway, BRAF typically enables the activation of MEK and ERK, and its mutation significantly promotes metastasis. However, whether BRAF could stimulate metastasis via a distinct manner is still unknown. Herein, we found that a portion of the BRAF protein localized at the plasma membrane and that the BRAFV600E mutation led to abundant formation of filopodia, which is a hallmark of invasive cancer cells. Mechanistically, BRAF physically interacts with the pseudopod formation-related protein Vasodilator-stimulated phosphoprotein (VASP), and BRAF specifically catalyzes VASP phosphorylation at Ser157. VASP depletion or disruption of Ser157 phosphorylation preferentially reduced the motility, invasion and metastasis of tumor cells harboring oncogenic BRAF or KRAS. Moreover, in clinical cancer tissues, BRAFV600E was positively correlated with the extent of invasion, and tissues with BRAFV600E expression exhibited elevated levels of VASP Ser157 phosphorylation. Our study therefor reveals a noncanonical mechanism by which oncogenic BRAF or KRAS promotes metastasis, suggests that VASP Ser157 phosphorylation might serve as a valuable therapeutic target in BRAF or KRAS mutant cancers.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (82173137, 82373047)
This publication has 42 references indexed in Scilit:
- Protein Kinase D1-mediated Phosphorylations Regulate Vasodilator-stimulated Phosphoprotein (VASP) Localization and Cell MigrationJournal of Biological Chemistry, 2013
- Filopodia and adhesion in cancer cell motilityCell Adhesion & Migration, 2011
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- Lysophosphatidic acid (LPA)‐induced vasodilator‐stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC‐3 prostate cancer cellsMolecular Oncology, 2008
- Structural basis for the recruitment of profilin–actin complexes during filament elongation by Ena/VASPThe EMBO Journal, 2007
- Raf kinases: Function, regulation and role in human cancerBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Fascin, a Novel Target of β-Catenin-TCF Signaling, Is Expressed at the Invasive Front of Human Colon CancerCancer Research, 2007
- Syndecan-2 induces filopodia and dendritic spine formation via the neurofibromin–PKA–Ena/VASP pathwayJournal of Cell Biology, 2007
- Mutations of the BRAF gene in human cancerNature, 2002